Heart failure & cardiomyopathies
EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy
Recommendations
As issued by the authors
Phenotypic classification, diagnosis with multimodal imaging and genetic testing, and SCD risk stratification
Pharmacologic pathways: beta-blockers, calcium channel blockers, disopyramide, cardiac myosin inhibitors (mavacamten, aficamten); indications for septal reduction therapies
Management of AF, hypertension, CAD, pregnancy, paediatric hypertrophic cardiomyopathy (HCM) and comorbidities
Controversies: optimal risk stratification models, genotype-positive/phenotype-negative individuals, exercise recommendations
Original publication
EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy. Eur J Heart Fail. Published 8 January 2026. doi:10.
Summarised from the published abstract; every number is checked against it